Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes

Inhibitors of poly(ADP‐ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In our study, of 182 women with EOC treated with PARPi, 16 (8.7%...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों: Todisco, Elisabetta, Gigli, Federica, Ronchini, Chiara, Amato, Viviana, Sammassimo, Simona, Pastano, Rocco, Parma, Gabriella, Lapresa, Maria Teresa, Bertolini, Francesco, Corsini, Chiara, Gregato, Giuliana, Poletti, Claudia, Pelicci, Pier Giuseppe, Alcalay, Myriam, Colombo, Nicoletta, Tarella, Corrado
स्वरूप: Online लेख मूलपाठ
भाषा:English
प्रकाशित: John Wiley & Sons, Inc. 2022
विषय:
Cancer Therapy and Prevention
ऑनलाइन पहुंच:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796966/
https://www.ncbi.nlm.nih.gov/pubmed/35695283
http://dx.doi.org/10.1002/ijc.34162

इंटरनेट

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796966/
https://www.ncbi.nlm.nih.gov/pubmed/35695283
http://dx.doi.org/10.1002/ijc.34162

समान संसाधन